Is Calliditas Therapeutics AB (publ) (CALT) a Buy, Sell, or Hold?
NASDAQ : CALT
Calliditas Therapeutics AB (publ)
$40.0001 USD
-$0.04 (-0.1%)
- Volume
- 9.8K
- Average Volume
- 7.59K
- Market Capitalization
- $2.15B
- P/E Ratio
- -21.92
- Dividend Yield
- 0.00%
- Price Target
- $39.50
- Year High
- $43.00
- Year Low
- $15.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.13
Company Overview
NASDAQ
Renee Aguiar-Lucander
Biotechnology
Healthcare
CALT
222
SE
USD
Liquidity Metrics
2.92
3.13
3.08
2.39
0.00
Sales & Valuation
$1.21B
16.95
30.54
-45.71
-16.67
Profitability
-$17.38
-$466.18M
-38.63%
-37.87%
-84.68%
-24.53%
P/E Metrics
-21.92
0.38
0.38
Analyst Price Target & Rating
$39.50
$40.00
$39.00
0/5
5 Analysts
1.27%
Financial Health Scores
8.19
2/9
$724.69M
$1.75B
$1.64B
-$363.9M
Key Metrics (TTM)
$20.42B
16.92
-55.52
3.13
-84.68%
-25.53%
-4.57%
-2.19%
-323 days
Company Executives
| Name | Title |
|---|---|
| Richard S. Philipson | Chief Medical Officer |
| Lars Stubberud | Vice President of Technical Operations |
| Brian Gorman | Group General Counsel |
| David Ferraro | Head of US Sales |
| Ann-Kristin Myde | Head of Clinical Development & Vice President of Project Management |
| Asa Hillsten | Head of IR & Sustainability |
| Renee Aguiar-Lucander | Chief Executive Officer |
| Sandra Frithiof | Vice President of Human Resources |
| Teona Johnson | Head of US Marketing |
| Fredrik Johansson | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock
Calliditas Therapeutics AB (publ) operates as a clinical-stage biopharmaceutical entity, committed to identifying, advancing, and commercializing therapeutic products. Its primary focus lies in developing treatments for rare (orphan) conditions, with a particular emphasis on disorders impacting the renal and hepatic systems. The company markets Nefecon, an orally administered formulation of budesonide, which functions as an immunosuppressive agent designed to address immunoglobulin A nephropathy, an autoimmune kidney disease. Its flagship investigational product is Setanaxib, a NOX inhibitor. Setanaxib is currently undergoing Phase 2b/3 clinical trials for primary biliary cholangitis. Furthermore, it is being evaluated in Phase 2 studies for various other indications, including squamous ce ... ll carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Calliditas's pipeline also includes Budenofalk 3 mg oral capsules, which are under development for the treatment of autoimmune hepatitis. The company was established in 2004 and has its corporate headquarters located in Stockholm, Sweden.
Frequently Asked Questions
-
What is the current Calliditas Therapeutics AB (publ) (CALT) stock price?
-
Calliditas Therapeutics AB (publ)(NASDAQ:CALT) stock price is $40.0001 in the last trading session. During the trading session, CALT stock reached the peak price of $43.0 while $15.25 was the lowest point it dropped to. The percentage change in CALT stock occurred in the recent session was --0.1% while the dollar amount for the price change in CALT stock was -$0.04.
-
CALT's industry and sector of operation?
-
The NASDAQ listed CALT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CALT?
-
Richard S. Philipson | Chief Medical Officer
Lars Stubberud | Vice President of Technical Operations
Brian Gorman | Group General Counsel
David Ferraro | Head of US Sales
Ann-Kristin Myde | Head of Clinical Development & Vice President of Project Management -
How many employees does CALT have?
-
Number of CALT employees currently stands at 222. CALT operates from Kungsbron 1, D5, Stockholm, None 111 22, SE.
-
Link for CALT official website?
-
Official Website of CALT is: https://www.calliditas.se
-
How do I contact CALT?
-
CALT could be contacted at phone #46 84 11 30 05 and can also be accessed through its website. CALT operates from Kungsbron 1, D5, Stockholm, None 111 22, SE.
-
How many shares of CALT are traded daily?
-
The average number of CALT shares traded daily for last 3 months was 7.59K.
-
What is the market cap of CALT currently?
-
The market value of CALT currently stands at $2.15B with its latest stock price at $40.0001